Sermorelin: The GHRH Analogue in Growth-Hormone Research
Sermorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue. Rather than introducing growth hormone directly, it is studied for its ability to stimulate the pituitary gland to release endogenous growth hormone — a mechanism of significant interest in growth-hormone-axis research.
What is Sermorelin?
Sermorelin corresponds to the biologically active fragment of GHRH. In research models it binds GHRH receptors in the anterior pituitary, prompting pulsatile release of growth hormone into circulation — a more physiologic pattern than exogenous GH administration, which is why it is a frequent comparator in secretagogue studies.
Key research areas
- GH-axis & aging models: investigating age-related decline in GH secretion and downstream IGF-1 signaling.
- Metabolic research: effects on lipolysis, insulin sensitivity, and body-composition endpoints in preclinical models.
- Recovery & tissue research: protein-synthesis and recovery markers, often studied alongside other secretagogues.
- Sleep-architecture research: GH secretion’s link to slow-wave sleep.
Considerations for Canadian researchers
- Regulatory status: not authorized by Health Canada for human use; research-chemical handling only.
- Quality & purity: source from reputable suppliers providing third-party testing and a COA.
- Handling: store lyophilized at −20°C, reconstitute with sterile bacteriostatic water using aseptic technique.
Explore related growth-hormone-secretagogue research compounds we carry: CJC-1295 DAC, Ipamorelin, and Tesamorelin — all third-party tested to over 99% purity with a COA. Pair with bacteriostatic water for reconstitution.
This guide is part of our Peptides Canada research hub — explore the full library of compound guides.
Disclaimer: Educational and research content only. Sermorelin is discussed strictly as a research chemical, not for human consumption or therapeutic use. All work must comply with Canadian regulations and institutional ethics approvals.
